Replies to post #714094 on NorthWest Biotherapeutics Inc (NWBO)

[Investor082]

Buyout or partnership makes the most sense in terms of their posture, but then our share price doesn’t support buyout at this time. So partnership or some sort of spin off with DCVAX-L as the quarterback remains the most viable option. It really doesn't matter if the partner is Merck, Pfizer, Astrazeneca or Regeneron. The important thing is we need a credible and experienced pharma team to back NWBO right away as soon as UK approval is announced. If they dangle any more carrot like Flaskworks, it will become clear there is really no interest in our platform from big or mid size pharma.

[AAPL31415926]

BO very possible. How about Merck, not a cash buyout but as an example 1 share MRK for 10 NWBO. Merck already has 2.53 billion shares, a 1 for 10 buyout would only cost Merck 170M shares. That's only about a 7% increase in share total and would get us about $12 per share. Of course 1 for 8 would be way better, but I also think either way, from what I read, there would be a nice issue with taxes.
Then again I'd like more.

[Kam8]

Hope BO ,$16.8 per share is good for me

[XMaster2023]

I don’t believe LP is going to give up control until DCVax-L is approved and has become the SOC. I would not say she is OLD.

[martyDg]

Approval from MHRA or FDA? Because maybe the next narrative after MHRA approval is BP is waiting for FDA approval before initiating BO.